Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Early Phase 1

3(42.9%)

Phase 3

2(28.6%)

Phase 1

1(14.3%)

Phase 2

1(14.3%)

7Total

Early Phase 1(3)

Phase 3(2)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06878833Phase 3Withdrawn

A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder

Role: lead

NCT05779241Phase 3Completed

Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

Role: lead

NCT04567524Phase 2Completed

A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules

Role: lead

NCT05251376Phase 1Withdrawn

Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy

Role: lead

NCT03468543Early Phase 1Terminated

Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

Role: lead

NCT03711825Early Phase 1Completed

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults

Role: lead

NCT03718390Early Phase 1Completed

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults

Role: lead

All 7 trials loaded